Presentation TCT 2015 Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit! Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo October 11, 2015
Presentation TCT 2015 Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks! Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser October 11, 2015
News Conference News TCT 2015 Experts Debate Optimal Pharmacologic Approach for STEMI Patients October 11, 2015
News Features TCT 2014 Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease Todd Neale October 24, 2014
Presentation TCT 2014 Con: Follow the Data and Save the Patient! Presenter: Adrian P. Banning, Gregg W. Stone September 16, 2014
Presentation TCT 2014 Pro: Follow the Data - and Save the Money! Presenter: Adrian P. Banning, Rod H. Stables September 16, 2014
Presentation TCT 2014 Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS Presenter: Timothy Henry September 16, 2014
Presentation TCT 2014 Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention Presenter: Ahmed Rehmani September 16, 2014
Presentation TCT 2014 Efficacy and safety of switching from clopidogrel to prasugrel in diabetic patients with acute coronary syndromes treated with drug-elunting stents: results of the ESCAPADA study Presenter: Armando P?rez de Prado September 16, 2014
Presentation TCT 2014 VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_ Presenter: Jos? Mar?a Cubero G?mez September 16, 2014
Presentation TCT 2014 Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE Presenter: Fausto Feres September 16, 2014
Presentation TCT 2014 Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation Presenter: Giulio Stefanini September 16, 2014
Presentation TCT 2014 Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_ Presenter: Naoei Isomura September 16, 2014
Presentation TCT 2014 Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction Presenter: Jun-Hyok Oh September 16, 2014
Presentation TCT 2014 Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy Presenter: Dietmar Trenk September 16, 2014
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014
Presentation TCT 2014 TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis September 15, 2014
Presentation TCT 2014 When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White September 15, 2014